Literature DB >> 19422028

Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population.

Joshua D Courter1, Joseph L Kuti, Jennifer E Girotto, David P Nicolau.   

Abstract

BACKGROUND: Administration of beta-lactams via prolonged or continuous infusion has been utilized in adults to optimize drug exposure and clinical outcomes. As children exhibit increased drug clearance, this may further the benefit of prolonged or continuous infusions. This dosing approach was applied to several beta-lactams commonly utilized in children. PROCEDURE: A variety of cefepime, ceftazidime, imipenem/cilastatin, meropenem, and piperacillin/tazobactam regimens using administration times of 0.5, 3, or 24 hr infusions were simulated in populations of 2- and 12-year-old children using Monte Carlo techniques. The probability of target attainment (PTA) was calculated for each dosing regimen. Minimum inhibitory concentration (MIC) frequencies for Pseudomonas aeruginosa were obtained for two pediatric acute care institutions in order to calculate cumulative fractions of response (CFR).
RESULTS: Standard 0.5 hr infusions resulted in poor PTA for most study agents at their susceptibility breakpoint, whereas 3 hr infusions markedly improved PTA for cefepime (79 to 100%), ceftazidime (80 to 100%), imipenem (41 to 91%), and meropenem (33 to 97%). Piperacillin/tazobactam could not achieve a PTA > 21% for any dosing regimen at its breakpoint, though large improvements were observed at lower MICs. Continuous infusion regimens resulted in similar PTA results to the same dose administered as 3 hr infusions. CFR values for all drugs at both institutions improved when 3 hr or continuous infusions were employed.
CONCLUSIONS: Prolonged and continuous infusion dosing strategies improved the likelihood of obtaining bactericidal targets for these beta-lactams in a simulated pediatric population. Based on these data, pediatric studies employing these strategies are warranted. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19422028     DOI: 10.1002/pbc.22051

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  26 in total

1.  Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies.

Authors:  Lei Dong; Xiao-Ying Zhai; Yi-Lei Yang; Li Wang; Yue Zhou; Hai-Yan Shi; Bo-Hao Tang; Yue-E Wu; Fan Yang; Li Wen; Hong-Xiao Kong; Li-Juan Zhi; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  Extended Infusion of Piperacillin/Tazobactam in Children.

Authors:  Chad A Knoderer; Lauren C Karmire; Katie L Andricopulos; Kristen R Nichols
Journal:  J Pediatr Pharmacol Ther       Date:  2017 May-Jun

3.  Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing.

Authors:  Mohammad H Al-Shaer; Michael N Neely; Jiajun Liu; Kartikeya Cherabuddi; Veena Venugopalan; Nathaniel J Rhodes; Kenneth Klinker; Marc H Scheetz; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

4.  Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children.

Authors:  Céline Thibault; Jean Lavigne; Catherine Litalien; Nastya Kassir; Yves Théorêt; Julie Autmizguine
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 5.  Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.

Authors:  Kathleen Chiotos; Molly Hayes; Jeffrey S Gerber; Pranita D Tamma
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

6.  Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patients.

Authors:  Piergiorgio Cojutti; Natalia Maximova; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

7.  Beyond Susceptible and Resistant, Part I: Treatment of Infections Due to Gram-Negative Organisms With Inducible β-Lactamases.

Authors:  Conan Macdougall
Journal:  J Pediatr Pharmacol Ther       Date:  2011-01

8.  Clinical Outcomes With Continuous Nafcillin Infusions in Children.

Authors:  Chad A Knoderer; Lauren C Karmire; Kristen R Nichols
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jul-Aug

Review 9.  Beyond Susceptible and Resistant, Part III: Treatment of Infections due to Gram-Negative Organisms Producing Carbapenemases.

Authors:  Navaneeth Narayanan; Linda Johnson; Conan MacDougall
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Mar-Apr

10.  Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Pediatric Patients.

Authors:  Jumpei Saito; Kensuke Shoji; Yusuke Oho; Hiroki Kato; Shotaro Matsumoto; Satoshi Aoki; Hidefumi Nakamura; Takanori Ogawa; Mayumi Hasegawa; Akimasa Yamatani; Isao Miyairi
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.